arrow
R

Robert Pytlík

Charles University
H指数:28
被引数:2,321

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic

捷克共和国近期接受三线及以上治疗弥漫性大B细胞淋巴瘤患者的生存改善

2026-01-010
OA
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

进展与治疗开始之间的间隔是复发性弥漫性大b细胞淋巴瘤的关键预后参数: 来自捷克淋巴瘤研究组数据库 (NIHIL) 的分析

2020-06-060
PREAI
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
2018-12-139
OAAI
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
2018-09-1312
PREAI
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma
2017-10-3017
PREAI
Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma
2017-07-010
PRE
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma (vol 22, pg 1138, 2016)
2016-07-311
OAAI
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2-and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
2016-02-2976
OAAI